{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/anti-obesity-drug-development-advances-challenges-and-mitigations-maximize-success#webpage",
"url": "https://www.fortrea.com/insights/anti-obesity-drug-development-advances-challenges-and-mitigations-maximize-success",
"name": "Anti-obesity drug development: advances, challenges and mitigations to maximize success",
"description": "This Fortrea white paper explores how the rapid growth of anti-obesity drugs is increasing complexity across obesity clinical trials and modern obesity research programs. The content focuses on evolving obesity clinical trial demands, patient recruitment challenges, long-term study requirements, operational pressures, and research complexity associated with expanding anti-obesity drug development activity. The white paper highlights challenges related to scaling obesity clinical trials, supporting long-term patient participation, managing increasing study demand, and adapting research strategies within evolving obesity therapeutic environments. Fortrea discusses considerations affecting obesity clinical trial execution and the growing need for flexible research approaches capable of supporting expanding anti-obesity drug research programs. By integrating operational planning with evolving obesity clinical research requirements, the white paper provides insights into the increasing complexity affecting obesity clinical trials and anti-obesity drug research environments."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Anti-obesity drug development: advances, challenges and mitigations to maximize success",
"item": "https://www.fortrea.com/insights/anti-obesity-drug-development-advances-challenges-and-mitigations-maximize-success"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/anti-obesity-drug-development-advances-challenges-and-mitigations-maximize-success#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/anti-obesity-drug-development-advances-challenges-and-mitigations-maximize-success#webpage"
},
"headline": "Anti-Obesity Drugs and the Evolving Complexity of Obesity Clinical Trials | Fortrea White Paper",
"description": "This Fortrea white paper explores how the rapid growth of anti-obesity drugs is increasing complexity across obesity clinical trials and modern obesity research programs. The content focuses on evolving obesity clinical trial demands, patient recruitment challenges, long-term study requirements, operational pressures, and research complexity associated with expanding anti-obesity drug development activity. The white paper highlights challenges related to scaling obesity clinical trials, supporting long-term patient participation, managing increasing study demand, and adapting research strategies within evolving obesity therapeutic environments. Fortrea discusses considerations affecting obesity clinical trial execution and the growing need for flexible research approaches capable of supporting expanding anti-obesity drug research programs. By integrating operational planning with evolving obesity clinical research requirements, the white paper provides insights into the increasing complexity affecting obesity clinical trials and anti-obesity drug research environments.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2024-10/GettyImages-1457946270_0.webpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2024-10-14",
"dateModified": "2024-10-14",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2024-10/WP_0054_Anti-Obesity%20Drug.pdf",
"encodingFormat": "application/pdf"
}
}
]
}